Sage Journals: Discover world-class research

Abstract

Investigative sites participating in clinical trials play an instrumental role in aiding market adoption. Site experiences in clinical research help physician investigators and research professionals gain familiarity with and exposure to investigational treatments. This knowledge may be passed on to sponsor companies and may ultimately assist in positioning new products and driving commercialization success. This study evaluates site characteristics that influence the acquisition and sharing of knowledge gained through clinical trial experience. The impact of 2 central site characteristics on the process of translating drug experience is assessed: site location (North America/rest of the world) and site type or setting (academic/independent). The results show that investigative sites located outside North America generate and share more knowledge than those within North America. Furthermore, although both academic and independent sites generate the same level of knowledge, academic sites share more of this knowledge with sponsor companies. This study suggests new strategies that sponsors can leverage to drive greater transfer of clinical research knowledge into clinical practice and ultimately improve the commercialization of newly launched therapies.

Keywords

site location academic sites independent sites translation opportunities knowledge transfer clinical practice insights

Get full access to this article

View all access options for this article.

References

Ploeg

Davies

Edwards

Gifford

Miller

. Factors influencing best-practice guideline implementation: lessons learned from administrators, nursing staff, and project leaders. Worldviews Evid Based Nurs. 2007;4:210–219.

Rettig

. The industrialization of clinical research. Health Affairs. 2000;19:2.

Sung

Crowley

Genel

. Central challenges facing the national clinical research enterprise. JAMA. 2003;289:1278–1287.

Lenfant

. Clinical research to clinical practice: lost in translation. N Engl J Med. 2003;349:868–874.

Nonaka

. A dynamic theory of organizational knowledge creation. Org Sci. 1994;5:1.

Teece

. Capturing value from knowledge assets: the new economy, market for know-how, and intangible assets. Cal Manag Rev. 1998;40:3.

Glass

. Patterns in prescribing behavior: the potential hidden costs of using CROs. Drug Info J. 2004;38:127–134.

Glass

. Do clinical grant payment practices in phase 3 clinical trials influences subsequent clinical investigators prescribing behavior? Dis Manag. 2004;7:1.

Corrigan

Glass

. Physicians participation in clinical studies and subsequent prescribing of new drugs. P T. 2005;30:1.

10.

Glass

Poli

. The dual role of company prescribing loyalty in new drug launches. J Pharm Market Manag. 2004;16:2.

11.

Jaakkola

Renko

. Critical innovation characteristics influencing the acceptability of a new pharmaceutical product format. J Market Manag. 2007;23:327–346.

12.

McGettigan

Golden

Fryer

Chan

Feely

. Prescribers prefer people: the sources of information used by doctors for prescribing suggest that the medium is more important than the message. J Clin Pharm. 2000;51;184–189.

13.

Soumerai

McLaughlin

Gurwitz

. Effect of local medical opinion leaders on quality of care for acute myocardial infarction. JAMA. 1998;17:1.

14.

Glass

Rosenthal

. Post-launch clinical investigator drug prescribing in the US: the behavior of clinical trial investigators after participating in phase III trials. Int J Pharm Med. 2005;19:2.

15.

Glass

Rosenthal

. The demographic, practice and prescribing characteristics of physicians who are early adopters of new drugs. P T. 2004;29:11.

16.

Fisher

. Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials. New Brunswick, NJ: Rutgers University Press; 2009.

17.

CenterWatch. State of the Clinical Trials Industry. Boston, MA: Thomson, CenterWatch; 2005.

18.

Bodenheimer

. Uneasy alliances: clinical investigators and the pharmaceutical industry. N Engl J Med. 2000;342:20.

19.

Getz

. Global clinical trials activity in the details. Applied Clinical Trials . September 1, 2007.

20.

Fabio

Thiers

Sinskey

Berndt

. Trends in the globalization of clinical trials. Nat Rev Drug Discov. 2008;7:13–14.

21.

Glickman

McHutchison

Peterson

. Ethical and scientific implications of the globalization of clinical trials. N Engl J Med. 2009;360:816–823.

22.

Knoke

Bohrnstedt

Mee

. Statistics for Social Data Analysis. 4th ed. Boston, MA: Wadsworth Cengage Learning; 2002.

23.

Wooldrige

. Introductory Econometrics. Cincinnati, OH: South-Western; 2009.

24.

Tabachnick

Fidell

. Using Multivariate Statistics. 5th ed. Boston, MA: Pearson Education; 2007.

25.

Azoulay

. Capturing within and across form boundaries: evidence from clinical development. Am Econ Rev. 2004;94:5.

26.

DiMasi

Hansen

Grabowski

. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185.

27.

Kaitin

Healy

. The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era. Drug Info J. 2000;34:1–14.

28.

Maiti

Raghavendra

. Clinical trials in India. Pharmacological Research 2007;56:1–10.

29.

Kaitin

. The landscape for pharmaceutical innovation. drivers for cost-effective clinical research. Pharmaceutical Outsourcing. 2010;2010:3605.

30.

Getz

Vogel

. Successful outsourcing: tracking global CRO usage. Appl Clin Trials. 2009;18:42–50.

31.

CenterWatch. [Press release concerning new research findings]. Boston, MA: CenterWatch; 2011.

Site Characteristics Influencing the Translation of Clinical Research Into Clinical Practice

Abstract

Keywords

Get full access to this article

References